PrematurityNCT05223192
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
A study testing Music Therapy Entrainment with Ocean Disc Intervention in people with Prematurity, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.
Trial summary
Infants born prematurely at will be asked to participate in this randomized controlled trial at a corrected gestational age of 24-37 weeks. Infants will be randomly selected to each of the two groups: intervention and control. Read more about this study
- Who is it for?
- Ages 24 to 37 weeks
- Conditions the study is for
- Prematurity
- What is being tested?
- Music Therapy Entrainment with Ocean Disc Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2022to 31 Dec 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 24 to 37 weeks
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Newborns born at 24-37 weeks' gestation at Mount Sinai hospital
- Newborn is considered appropriate for clinically indicated music therapy
Who cannot join
- Infant not expected to survive 24 hours from the time of study entry (To be assessed by a member of the NICU Faculty other than the PI)
- Infant of uncertain viability (gestation <23 weeks, birth weight <500 grams)
- Known or suspected genetic disorder (e.g., Trisomy 21)
- Identified hearing disorder
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Mount Sinai Hospitals
New York, New York, 10003
Joanne V Loewy, DA, LCAT, MT-BC, (212) 420-3484, joanne.loewy@mountsinai.org
Joanne V Loewy
About this study
Infants born prematurely at will be asked to participate in this randomized controlled trial at a corrected gestational age of 24-37 weeks. Infants will be randomly selected to each of the two groups: intervention and control. Infants in the treatment group will receive six intervention days over a two-week period, 3 sessions per week. Each intervention day consists of each of the two interventions in a random sequence: no intervention/silence and live ocean disc instrument intervention. The sound decibel level will also be recorded and maintained at 40-65dB to prevent overstimulation. Each infant will thus receive control and ocean disc intervention on the same day in the NICU. Interventions will be given in a randomized order (i.e., first ocean disc or first silence, randomized to AM or PM), with observation occurring for 10 minutes before each intervention, 15 minutes during each intervention, and 10 minutes after each per session. There will be 3 sessions per week for a two-week randomized treatment schedule. For each infant, data on total apnea time, mean respiratory rate, heart rate, O2 levels and behavior rating during will be collected. The sound decibel level will also be recorded and maintained at 40-65dB to prevent overstimulation and hearing damage. Near-infrared light spectroscopy (NIRS) data on cerebral oxygenation will also be collected. Observations will be recorded on the infant's activity or when change occurs, such as a pacifier falling out. Parents and nurses will be asked to behave as they normally would during routine care.
- Conditions
- Prematurity
- Being tested
- Music Therapy Entrainment with Ocean Disc Intervention
- Keywords
- music therapy, ocean disc, prematurity, vital signs, cerebral oxygenation
- Medical subject headings
- Premature Birth
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Music Therapy Entrainment with Ocean Disc InterventionBehavioural
The studied intervention regards live entrainment with the ocean disc. Entrainment involves the use of an external stimulus, in the case of this study, an ocean disc instrument. Motion of the disc creates sounds in synchrony with the breathing of the infant and then in turn can control and influence the infant's regulation of the breath.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | Participants in this group will receive the ocean disc music therapy entrainment intervention Receives: Behavioral: Music Therapy Entrainment with Ocean Disc Intervention |
| Control group | No intervention | Participants in this group will not receive any intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Heart Rate
Measured: 14 days
Respiratory Rate
Measured: 14 days
Oxygen-Saturation Level
Measured: 14 days
Weight
Measured: 14 days
Cerebral oxygen saturation
Cerebral oxygen saturation measured using NIRS
Measured: 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2022
- Study start1 Apr 2022
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PrematurityStudies of the same condition, open and under way.
- More trials run by Icahn School of Medicine at Mount SinaiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Joanne Loewy, Icahn School of Medicine at Mount Sinai
- Investigators
- Joanne V Loewy, DA, MT-BC, LCAT, Principal investigator, Icahn School of Medicine at Mount Sinai
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05223192
- Sponsor's protocol ID
- STUDY-21-01783
- Status last verified
- Aug 2026
- First submitted
- 24 Jan 2022
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will be made available upon reasonable request to corresponding author